NasdaqGS:ROIVBiotechs
A Look At Roivant Sciences (ROIV) Valuation As Analyst Upgrades And Brepocitinib Progress Lift Sentiment
Roivant Sciences (ROIV) is back in focus after a cluster of upbeat analyst ratings coincided with progress in its brepocitinib program, along with mixed clinical news from Immunovant’s autoimmune pipeline.
See our latest analysis for Roivant Sciences.
At a share price of US$28.21, Roivant’s recent 90 day share price return of 20.35% and 1 year total shareholder return of 176.84% indicate strong recent momentum as brepocitinib progresses and analyst sentiment remains supportive.
If this kind...